These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 36174258

  • 1. Fingolimod, teriflunomide and cladribine for the treatment of multiple sclerosis in women of childbearing age: description of drug utilization and exposed pregnancies in Germany.
    Platzbecker K, Wentzell N, Kollhorst B, Haug U.
    Mult Scler Relat Disord; 2022 Nov; 67():104184. PubMed ID: 36174258
    [Abstract] [Full Text] [Related]

  • 2. Use of leflunomide among girls and women of childbearing age and occurrence of leflunomide-exposed pregnancies in Germany.
    Princk C, Kollhorst B, Haug U.
    Reprod Toxicol; 2024 Apr; 125():108573. PubMed ID: 38460863
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Use of Methotrexate in Girls and Women of Childbearing Age, Occurrence of Methotrexate-Exposed Pregnancies and Their Outcomes in Germany: A Claims Data Analysis.
    Wentzell N, Kollhorst B, Reinold J, Haug U.
    Clin Drug Investig; 2023 Feb; 43(2):109-117. PubMed ID: 36542272
    [Abstract] [Full Text] [Related]

  • 6. Comparative effectiveness of cladribine tablets versus fingolimod in the treatment of highly active multiple sclerosis: A real-world study.
    Brownlee WJ, Haghikia A, Hayward B, Waser N, Kayaniyil S, Khan Z, Duncan J, Millar S, Harty GT.
    Mult Scler Relat Disord; 2023 Aug; 76():104791. PubMed ID: 37343465
    [Abstract] [Full Text] [Related]

  • 7. Comparative effectiveness of cladribine tablets versus other oral disease-modifying treatments for multiple sclerosis: Results from MSBase registry.
    Spelman T, Ozakbas S, Alroughani R, Terzi M, Hodgkinson S, Laureys G, Kalincik T, Van Der Walt A, Yamout B, Lechner-Scott J, Soysal A, Kuhle J, Sanchez-Menoyo JL, Blanco Morgado Y, Spitaleri D, van Pesch V, Horakova D, Ampapa R, Patti F, Macdonell R, Al-Asmi A, Gerlach O, Oh J, Altintas A, Tundia N, Wong SL, Butzkueven H.
    Mult Scler; 2023 Feb; 29(2):221-235. PubMed ID: 36433775
    [Abstract] [Full Text] [Related]

  • 8. [Comments on the GLIMPSE study on evaluating the efficacy of the drug cladribine in tablets in routine clinical practice in comparison with other tablet drugs for the pathogenetic treatment of multiple sclerosis].
    Boyko AN.
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022 Feb; 122(7. Vyp. 2):73-77. PubMed ID: 35912560
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of cladribine tablets versus fingolimod in patients with highly active relapsing multiple sclerosis in Portugal.
    Pinheiro B, Guerreiro R, Costa J, Miguel LS.
    J Med Econ; 2020 May; 23(5):484-491. PubMed ID: 31951777
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Cladribine (Mavenclad) for multiple sclerosis.
    Med Lett Drugs Ther; 2019 Jul 29; 61(1577):118-120. PubMed ID: 31381552
    [No Abstract] [Full Text] [Related]

  • 12. The CLARION study design and status update: a long-term, registry-based study evaluating adverse events of special interest in patients with relapsing multiple sclerosis newly started on cladribine tablets.
    Butzkueven H, Moore N, Aydemir A, Sõnajalg J, Bezemer I, Korhonen P, Sabidó M, CLARION Study Group.
    Curr Med Res Opin; 2022 Jul 29; 38(7):1167-1176. PubMed ID: 35357268
    [Abstract] [Full Text] [Related]

  • 13. Benefit-risk Assessment of Cladribine Using Multi-criteria Decision Analysis (MCDA) for Patients With Relapsing-remitting Multiple Sclerosis.
    Vermersch P, Martinelli V, Pfleger C, Rieckmann P, Alonso-Magdalena L, Galazka A, Dangond F, Phillips L.
    Clin Ther; 2019 Feb 29; 41(2):249-260.e18. PubMed ID: 30846120
    [Abstract] [Full Text] [Related]

  • 14. Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis.
    Nygaard GO, Torgauten H, Skattebøl L, Høgestøl EA, Sowa P, Myhr KM, Torkildsen Ø, Celius EG.
    Mult Scler Relat Disord; 2022 Jun 29; 62():103812. PubMed ID: 35462167
    [Abstract] [Full Text] [Related]

  • 15. Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis.
    Mankinen P, Lundström T, Soini E, Sumelahti ML, Ruutiainen J, Niskala U, Järvinen E.
    Adv Ther; 2020 Feb 29; 37(2):800-818. PubMed ID: 31873868
    [Abstract] [Full Text] [Related]

  • 16. Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis.
    Kalincik T, Kubala Havrdova E, Horakova D, Izquierdo G, Prat A, Girard M, Duquette P, Grammond P, Onofrj M, Lugaresi A, Ozakbas S, Kappos L, Kuhle J, Terzi M, Lechner-Scott J, Boz C, Grand'Maison F, Prevost J, Sola P, Ferraro D, Granella F, Trojano M, Bergamaschi R, Pucci E, Turkoglu R, McCombe PA, Pesch VV, Van Wijmeersch B, Solaro C, Ramo-Tello C, Slee M, Alroughani R, Yamout B, Shaygannejad V, Spitaleri D, Sánchez-Menoyo JL, Ampapa R, Hodgkinson S, Karabudak R, Butler E, Vucic S, Jokubaitis V, Spelman T, Butzkueven H.
    J Neurol Neurosurg Psychiatry; 2019 Apr 29; 90(4):458-468. PubMed ID: 30636699
    [Abstract] [Full Text] [Related]

  • 17. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G.
    Cochrane Database Syst Rev; 2017 Apr 25; 4(4):CD012200. PubMed ID: 28440858
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of Cladribine Tablets and fingolimod in the treatment of relapsing multiple sclerosis with high disease activity in Spain.
    Poveda JL, Trillo JL, Rubio-Terrés C, Rubio-Rodríguez D, Polanco A, Torres C.
    Expert Rev Pharmacoecon Outcomes Res; 2020 Jun 25; 20(3):295-303. PubMed ID: 31220959
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis.
    Paolicelli D, Manni A, Iaffaldano A, Trojano M.
    CNS Drugs; 2020 Jan 25; 34(1):65-92. PubMed ID: 31898276
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.